Last reviewed 2026-06-01 · How we verify

Ferricon (CIDEFERRON)

Phase 2 active ✓ Verified Jun 2026

Ferricon (generic name: CIDEFERRON) is a drug. It is currently in Phase 2 development.

Ferricon is a small molecule that works by binding to a specific target to exert its therapeutic effect.

Ferricon is also known as CIDEFERRON, FERRIC CITRATE DEXTRIN COMPLEX. The modality of Ferricon is currently unknown.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CIDEFERRON
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine Ferricon as a key that fits into a lock on a cell. When it binds to its target, it helps to regulate the cell's behavior and can potentially treat a specific disease or condition. This is a simplified explanation of how Ferricon works at a molecular level.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ferricon CI brief — competitive landscape report
Ferricon updates RSS · CI watch RSS

Frequently asked questions about Ferricon

What is Ferricon?

Ferricon (CIDEFERRON) is a pharmaceutical drug.

How does Ferricon work?

Ferricon is a small molecule that works by binding to a specific target to exert its therapeutic effect.

What is the generic name of Ferricon?

CIDEFERRON is the generic (nonproprietary) name of Ferricon.

What development phase is Ferricon in?

Ferricon is in Phase 2.

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing